Sugi Predict

Sugi Predict / Compounds / SCHEMBL577687

SCHEMBL577687

SCHEMBL577687

O=C(O)c1ccc(OCCOCCOCCOc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.78
▸ RARB P10826 4/20 0.73
▸ MAPK1 P28482 2/20 0.62
▸ TSHR P16473 2/20 0.62
▸ TP53 P04637 1/20 0.62
▸ PLA2G4B P0C869 4/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ USP2 O75604 1/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ HTT P42858 1/20 0.57
▸ NR4A1 P22736 1/20 0.56
▸ NR4A2 P43354 1/20 0.56
▸ NR4A3 Q92570 1/20 0.56
▸ PARP10 Q53GL7 1/20 0.56
▸ RXRA P19793 1/20 0.56
▸ RXRB P28702 1/20 0.56
▸ MAPT P10636 1/20 0.55
▸ PLA2G4A P47712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13918671 1.00 PKM (0.78) PKMRARBMAPK1TSHRTP53
SCHEMBL20502046 1.00 PKM (0.78) PKMRARBMAPK1TSHRTP53
SCHEMBL4509186 1.00 PKM (0.78) PKMRARBMAPK1TSHRTP53
SCHEMBL196110 0.94 PKM (0.88) PKMRARBMAPK1TSHRTP53
SCHEMBL6860559 0.93 PKM (0.68) PKMRARBMAPK1TSHRTP53
SCHEMBL5721909 0.93 PKM (0.68) PKMRARBMAPK1TSHRTP53
SCHEMBL15562010 0.91 RARB (0.68) PKMRARBMAPK1TSHRTP53
SCHEMBL22495314 0.91 PKM (0.66) PKMRARBMAPK1TSHRTP53
SCHEMBL22495487 0.91 PKM (0.66) PKMRARBMAPK1TSHRTP53
SCHEMBL9019628 0.91 RARB (0.68) PKMRARBMAPK1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024238983-A1 SARBECOVIRUS NANOVACCINES IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2024-11-21 — — WO claimed
US-10874737-B2 Influenza nanovaccine IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2020-12-29 — — US claimed
US-20200129429-A1 BIOCOMPATIBLE AND BIODEGRADABLE EMULSIONS AND COMPOSITIONS, AND METHODS OF USE THEREOF VIVAVAX INC. (CA) 2020-04-30 — — US claimed
US-10130454-B2 Vaccine delivery devices IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2018-11-20 — — US claimed
WO-2018167715-A1 BIOCOMPATIBLE AND BIODEGRADABLE EMULSIONS AND COMPOSITIONS, AND METHODS OF USE THEREOF VIVAVAX INC. (CA) 2018-09-20 — — WO claimed
US-20160030146-A1 VACCINE DELIVERY DEVICES IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2016-02-04 — — US claimed
US-20250275922-A1 THERMOSTABLE PARTICLE-BASED COMPOSITIONS AND MANUFACTURING PROCESS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2025-09-04 — — US disclosed
US-20250236645-A1 MRNA EXPRESSION AND DELIVERY SYSTEMS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2025-07-24 — — US disclosed
WO-2024238983-A1 SARBECOVIRUS NANOVACCINES IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2024-11-21 — — WO disclosed
WO-2024238983-A1 SARBECOVIRUS NANOVACCINES IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2024-11-21 — — WO disclosed
CN-118715326-A MRNA expression and delivery system 衣阿华州立大学研究基金公司 2024-09-27 — — CN disclosed
US-20230049529-A1 MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE ALNYLAM PHARMACEUTICALS, INC. (US) 2023-02-16 — — US disclosed
US-10881720-B2 Nanoparticles for immune stimulation THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-01-05 — — US disclosed
US-20100323961-A1 SURFACE ERODING SUTURES TYCO HEALTHCARE GROUP LP (US) 2010-12-23 — — US disclosed
US-20100021519-A1 Compositions and Methods for Treating or Preventing Diseases of Body Passageways SHENOY NARMADA 2010-01-28 — — US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed
EP-2019649-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS Shenoy, Narmada R. (US) 2009-02-04 — — EP disclosed
US-20080195147-A1 SURFACE ERODING BARBED SUTURES TYCO HEALTHCARE GROUP LP (US) 2008-08-14 — — US disclosed
EP-1955720-A1 Surface eroding barbed sutures Tyco Healthcare Group, LP (US) 2008-08-13 — — EP disclosed
WO-2007127488-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS SHENOY NARMADA R (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129429-A1 BIOCOMPATIBLE AND BIODEGRADABLE EMULSIONS AND COMPOSITIONS, AND METHODS OF USE THEREOF LIPA, PNLIP, MGLL PKM 1990/4885RARB 2459/4885MAPK1 4357/4885
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 PKM 2337/4885RARB 445/4885MAPK1 488/4885
US-20250275922-A1 THERMOSTABLE PARTICLE-BASED COMPOSITIONS AND MANUFACTURING PROCESS TSLP, CHMP4B, TREH PKM 3746/4885RARB 3886/4885MAPK1 4597/4885
US-20230049529-A1 MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE EIF2AK2, ADAR, CD2BP2 PKM 4710/4885RARB 1167/4885MAPK1 4807/4885
US-20250236645-A1 MRNA EXPRESSION AND DELIVERY SYSTEMS PCNP, NSUN3, SARNP PKM 2060/4885RARB 3334/4885MAPK1 4422/4885
US-10874737-B2 Influenza nanovaccine CXCL10, LY96, USP24 PKM 4007/4885RARB 2793/4885MAPK1 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.